|Articles|June 12, 2002

FDA clears breast biopsy device

Advanced Imaging Technologies has received marketing clearance from the FDA for a breast biopsy on its Avera Breast Imaging System. Unlike conventional ultrasound scanners, Avera uses diffractive, or "through-wave," ultrasound. The biopsy capability will

Advanced Imaging Technologies has received marketing clearance from the FDA for a breast biopsy on its Avera Breast Imaging System. Unlike conventional ultrasound scanners, Avera uses diffractive, or "through-wave," ultrasound. The biopsy capability will allow physicians to perform immediate biopsies on suspicious breast masses during an Avera imaging session, according to the company.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Latest CME